aTyr Pharma, Inc. Stock Deutsche Boerse AG
Equities
471A
US0021202025
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.57 EUR | +1.29% | +7.53% | +21.71% |
May. 02 | ATyr Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 02 | Earnings Flash (LIFE) ATYR PHARMA Reports Q1 Revenue $235,000 | MT |
Sales 2024 * | 325K 301K | Sales 2025 * | 7.46M 6.92M | Capitalization | 115M 107M |
---|---|---|---|---|---|
Net income 2024 * | -62M -57.51M | Net income 2025 * | -60M -55.66M | EV / Sales 2024 * | 354 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 15.4 x |
P/E ratio 2024 * |
-1.84
x | P/E ratio 2025 * |
-2.16
x | Employees | 58 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.42% |
Latest transcript on aTyr Pharma, Inc.
1 day | +1.29% | ||
1 week | +7.53% | ||
Current month | +7.53% | ||
1 month | -6.55% | ||
3 months | +4.67% | ||
6 months | +40.18% | ||
Current year | +21.71% |
Managers | Title | Age | Since |
---|---|---|---|
Sanjay Shukla
CEO | Chief Executive Officer | 52 | 16-03-29 |
Jill Broadfoot
DFI | Director of Finance/CFO | 63 | 18-07-29 |
Lisa Carey
CTO | Chief Tech/Sci/R&D Officer | - | 15-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Schimmel
FOU | Founder | 83 | 05-09-07 |
Tim Coughlin
CHM | Chairman | 57 | 17-04-09 |
John Clarke
BRD | Director/Board Member | 70 | 05-08-31 |
Date | Price | Change |
---|---|---|
24-05-09 | 1.57 | +1.29% |
24-05-08 | 1.55 | +2.65% |
24-05-07 | 1.51 | +3.42% |
24-05-06 | 1.46 | 0.00% |
24-05-03 | 1.46 | +1.39% |
Delayed Quote Deutsche Boerse AG, May 09, 2024 at 07:30 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+23.37% | 46.71B | |
+48.83% | 41.8B | |
-0.94% | 41.52B | |
-5.86% | 29.55B | |
+11.29% | 25.78B | |
-20.92% | 19.26B | |
+3.20% | 12.14B | |
-2.67% | 12.08B | |
+30.23% | 11.98B |
- Stock Market
- Equities
- LIFE Stock
- 471A Stock